Literature DB >> 17290307

High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2.

Giovanna Maria Pierantoni1, Cinzia Rinaldo, Marcella Mottolese, Anna Di Benedetto, Francesco Esposito, Silvia Soddu, Alfredo Fusco.   

Abstract

High-mobility group A1 (HMGA1) overexpression and gene rearrangement are frequent events in human cancer, but the molecular basis of HMGA1 oncogenic activity remains unclear. Here we describe a mechanism through which HMGA1 inhibits p53-mediated apoptosis by counteracting the p53 proapoptotic activator homeodomain-interacting protein kinase 2 (HIPK2). We found that HMGA1 overexpression promoted HIPK2 relocalization in the cytoplasm and inhibition of p53 apoptotic function, while HIPK2 overexpression reestablished HIPK2 nuclear localization and sensitivity to apoptosis. HIPK2 depletion by RNA interference suppressed the antiapoptotic effect of HMGA1, which indicates that HIPK2 is the target required for HMGA1 to repress the apoptotic activity of p53. Consistent with this process, a strong correlation among HMGA1 overexpression, HIPK2 cytoplasmic localization, and low spontaneous apoptosis index (comparable to that observed in mutant p53-carrying tumors) was observed in WT p53-expressing human breast carcinomas. Hence, cytoplasmic relocalization of HIPK2 induced by HMGA1 overexpression is a mechanism of inactivation of p53 apoptotic function that we believe to be novel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17290307      PMCID: PMC1784001          DOI: 10.1172/JCI29852

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

Review 1.  p53: death star.

Authors:  K H Vousden
Journal:  Cell       Date:  2000-11-22       Impact factor: 41.582

2.  High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity.

Authors:  G M Pierantoni; C Rinaldo; F Esposito; M Mottolese; S Soddu; A Fusco
Journal:  Cell Death Differ       Date:  2005-12-09       Impact factor: 15.828

3.  Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide.

Authors:  A G Ostermeyer; E Runko; B Winkfield; B Ahn; U M Moll
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

4.  High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases.

Authors:  G Chiappetta; G Manfioletti; F Pentimalli; N Abe; M Di Bonito; M T Vento; A Giuliano; M Fedele; G Viglietto; M Santoro; T Watanabe; V Giancotti; A Fusco
Journal:  Int J Cancer       Date:  2001-01-15       Impact factor: 7.396

5.  Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.

Authors:  Eun-Joo Kim; Jong-Sup Park; Soo-Jong Um
Journal:  J Biol Chem       Date:  2002-03-29       Impact factor: 5.157

6.  Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP.

Authors:  Qinghong Zhang; Yasuhiro Yoshimatsu; Jeffrey Hildebrand; Steven M Frisch; Richard H Goodman
Journal:  Cell       Date:  2003-10-17       Impact factor: 41.582

Review 7.  The p53 response to DNA damage.

Authors:  David W Meek
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

8.  Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization.

Authors:  Y Tamimi; H G van der Poel; M M Denyn; R Umbas; H F Karthaus; F M Debruyne; J A Schalken
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

9.  Thyroid cell transformation requires the expression of the HMGA1 proteins.

Authors:  Maria Teresa Berlingieri; Giovanna M Pierantoni; Vincenzo Giancotti; Massimo Santoro; Alfredo Fusco
Journal:  Oncogene       Date:  2002-05-02       Impact factor: 9.867

10.  HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels.

Authors:  Y Wang; K M Debatin; H Hug
Journal:  BMC Mol Biol       Date:  2001-08-10       Impact factor: 2.946

View more
  37 in total

Review 1.  High mobility group proteins and their post-translational modifications.

Authors:  Qingchun Zhang; Yinsheng Wang
Journal:  Biochim Biophys Acta       Date:  2008-05-10

Review 2.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

3.  Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells.

Authors:  Y Huang; A Chuang; H Hao; C Talbot; T Sen; B Trink; D Sidransky; E Ratovitski
Journal:  Cell Death Differ       Date:  2011-01-28       Impact factor: 15.828

4.  High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells.

Authors:  Yunzhi Zhang; Teng Ma; Shuping Yang; Mingying Xia; Jing Xu; Haijia An; Yajun Yang; Shilin Li
Journal:  Mol Cell Biochem       Date:  2011-06-09       Impact factor: 3.396

Review 5.  Posttranslational modifications regulate HIPK2, a driver of proliferative diseases.

Authors:  Vera V Saul; M Lienhard Schmitz
Journal:  J Mol Med (Berl)       Date:  2013-04-25       Impact factor: 4.599

6.  Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis.

Authors:  Massimiliano Mellone; Christian Rinaldi; Isabella Massimi; Marialaura Petroni; Veronica Veschi; Claudio Talora; Silvia Truffa; Helena Stabile; Luigi Frati; Isabella Screpanti; Alberto Gulino; Giuseppe Giannini
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

7.  Interaction between HMGA1 and retinoblastoma protein is required for adipocyte differentiation.

Authors:  Francesco Esposito; Giovanna Maria Pierantoni; Sabrina Battista; Rosa Marina Melillo; Stefania Scala; Paolo Chieffi; Monica Fedele; Alfredo Fusco
Journal:  J Biol Chem       Date:  2009-07-26       Impact factor: 5.157

8.  High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Flavio Rocha; Evan Matros; Mark Redston; Edward Whang
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

9.  Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.

Authors:  Lavinia Nardinocchi; Rosa Puca; Ada Sacchi; Gideon Rechavi; David Givol; Gabriella D'Orazi
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

10.  HIPK2 modulates p53 activity towards pro-apoptotic transcription.

Authors:  Rosa Puca; Lavinia Nardinocchi; Ada Sacchi; Gideon Rechavi; David Givol; Gabriella D'Orazi
Journal:  Mol Cancer       Date:  2009-10-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.